Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer (UFUR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00890188|
Recruitment Status : Unknown
Verified May 2009 by National Cheng-Kung University Hospital.
Recruitment status was: Recruiting
First Posted : April 29, 2009
Last Update Posted : May 7, 2009
Colorectal cancer is a major health problem in Western society contributing to a high mortality rate. Treatment options for the majority of patients with metastases are limited to cytotoxic chemotherapies. The first line chemotherapy containing with oxaliplatin is recommend by guideline. The use of antiangiogenic agents, either alone or in combination with other therapies may provide an alternative treatment modality in the management of these patients. Metronomic chemotherapy refers to the close, regular administration of a chemotherapeutic drug, over prolonged periods. The advantages of metronomic chemotherapy include reducing acute toxicities and sometimes surprisingly good activity against drug resistant tumors via antiangiogenic effect.
Thalidomide is an agent, which has shown potential in the treatment of hematological and solid tissue malignancies such as multiple myeloma via antiangiogenic mechanism. Tegafur/uracil (UFUR) is one of the effective chemotherapeutics reported to be an effective antiangiogenic agent in an animal model of metastatic colorectal cancers (CRCs).
In the present study, the investigators will try to use low dose metronomic schedule of thalidomide with tegafur/uracil regimen to see the anti tumor efficacy in recurrent and metastasis colorectal cancer patients after oxaliplatin-contained chemotherapy.
The primary endpoints are overall response rate and clinical benefit and the secondary endpoint were to determine the progression free survival, and duration of objective response, the overall survival (OS) and to assess the safety profile. This is a prospective phase II study. After having checked all eligibility criteria, patients will be treated with Tegafur/Uracil (TU) regimen. About 34 patients will be enrolled.
|Condition or disease||Intervention/treatment||Phase|
|Colon Cancer||Drug: THALIDOMIDE and UFUR||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||34 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Feasibility of Combing THALIDOMIDE and UFUR in the Treatment of Advanced Colorectal Cancer After Oxaliplatin-Contained Chemotherapy|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||June 2011|
|Experimental: THALIDOMIDE and UFUR||
Drug: THALIDOMIDE and UFUR
T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
- Overall response(CR+PR) and Clinical benefit (CR+PR+SD) [ Time Frame: 3 months ]
- To determine the progression free survival, overall survival (OS)and assess the safety profile [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00890188
|Contact: Peng Chan Lin, MD||+886-062353535 ext email@example.com|
|National Cheng-Kung University Hospital||Recruiting|
|Tainan, Taiwan, 704|
|Contact: Peng Chan Lin, MD +886-06-2353535 ext 4559 firstname.lastname@example.org|
|Principal Investigator: Peng Chan Lin, MD|
|Principal Investigator:||Peng Chan Lin, MD||National Cheng-Kung University Hospital, Clinical Trial Center|